for Levodopa-Induced Dyskinesia
PolyCore’s PCT-3012 novel dopamine D3 receptor agonist is designed to modify how L-dopa works instead of negating its effects, to improve motor symptoms without the development of tolerance, dyskinesia or impulsive behaviors.
Levodopa (L-dopa), discovered in the late 1960s, is still the gold standard gold standard for treating PD symptoms today.
After 4-10 years of treatment, ~50% of patients experience “L-dopa induced dyskinesia” (LID).
LID manifests as abnormal involuntary body movements that can interfere with daily life.
How can PCT-3012’s differentiated mechanism of action address other CNS disorders?